HR Execs on the Move

Presbyterian Senior Living

www.presbyterianseniorliving.org

 
Supportive. Innovative. Compassionate. Presbyterian Senior Living is a not-for-profit organization, providing retirement and senior care services for more than 85 years. Headquartered in Dillsburg, Pennsylvania, we and our affiliates provide comprehensive services and accommodations to more than 6,000 seniors in 30 locations across the mid-Atlantic region of Pennsylvania, Maryland, Ohio and Delaware. Guided by the life and teachings of Jesus, the mission of Presbyterian Senior Living is to provide compassionate, vibrant and supportive communities and services to promote wholeness of body, mind and spirit.
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Jessica Lelii
Corporate Director of Human Resources Profile

Similar Companies

Odyssey Healthcare

Odyssey Healthcare is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Areta Crowell Ctr

Areta Crowell Ctr is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Washington Regional Transplant Consortium

Washington Regional Transplant Consortium is a Annandale, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeStation

LifeStation is a Union, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.